Berg is a Swiss private company located in Berg, with subsidiaries in Spain, providing investment services.

Part of OPKO Health, Inc., OPKO Ireland Global Holdings Ltd. is a company headquartered in Ireland. The firm functions as an investment holding company.

Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

EirGen Pharma focuses on the development, registration and commercial manufacture of high potency, high barrier to entry solid dose products for the global pharmaceutical market. EirGen Pharma is fully licensed to manufacture oncology, cytotoxic, steroidal and immunosuppressant molecules in a purpose built high containment facility. The state of the art facilities can also handle the development of moisture sensitive molecules in a low humidity environment. The company has an Investigational Medicinal Products (IMP) licence for the manufacture of clinical trial materials and a Manufacturing Licence for commercial manufacturing and packaging.

OPKO Renal LLC, a subsidiary of OPKO Health, Inc., is a company headquartered in Canada that manufactures pharmaceutical products.

Part of OPKO Health, Inc., Proventiv Therapeutics LLC is a company headquartered in Fitchburg, WI. The firm develops vitamin D therapeutics. It was founded by Eric J. Messner, Charles W. Bishop and Keith Crawford. Cytochroma, Inc. acquired Proventiv Therapeutics LLC on June 29, 2006.

Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

OrgaNext Research is a biopharmaceutical company focused on the development of medicines that restore muscle strength and battle muscular atrophy in older patients. The privately owned company is founded by former Organon executives in 2009 and is based in Arnhem, the Netherlands.Developer and provider of aging related food products and medicines. The company develops recovery booster therapies for stimulating the proliferation of satellite cells. It also develops medicines including hip fracture medicines to recover physical strength after injury and hospitalization.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Mercian Corporation is a Tokyo-based operating unit of Kirin, primarily engaged in the production and retail of wine and other alcoholic beverages. Chateau Mercian, produced and sold in Japan, is one of the most widely available brands of Japanese wine. Mercian Corporation also markets imported wine such as Casillero del Diablo, Frontera, and Sunrise brands in partnership with Concha y Toro, a leading Chilean wine producer.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.